

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PAR PHARMACEUTICAL, INC.,  
Petitioner,

v.

HORIZON THERAPEUTICS, LLC,  
Patent Owner.

---

Case IPR: Unassigned  
U.S. Patent No. 9,561,197

---

**PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,561,197  
UNDER 35 U.S.C. §§ 311-319 AND 37 C.F.R. §§ 42.1-.80, 42.100-.123**

*Mail Stop "PATENT BOARD"*  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

I. INTRODUCTION .....1

II. GROUNDS FOR STANDING (37 C.F.R. § 42.104(a)).....4

III. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE .....5

IV. OVERVIEW .....5

    A. POSA.....5

    B. Scope and Content of the Prior Art Before April 20, 2012.....6

        1. The Urea Cycle and UCDs .....6

        2. Nitrogen Scavenging Drugs .....8

        3. PAA Was Known to Cause Neurotoxicity At High Levels.....11

        4. PAA’s Conversion to PAGN Was Known to Be Saturable.....14

    C. Summary of the ’197 Patent.....16

        1. Brief Description of the ’197 Patent .....16

        2. The ’197 Patent Claims.....16

        3. Prosecution Background and Summary of Arguments .....17

V. CLAIM CONSTRUCTION .....23

    A. The Preambles .....24

    B. “a plasma PAA to PAGN ratio within the target range of 1 to 2” and “a plasma PAA to PAGN ratio within the target range of 1 to 2.5” .....28

VI. IDENTIFICATION OF THE CHALLENGE (37 C.F.R. § 42.104(b)) .....31

    A. Ground 1: Claims 1 and 2 Would Have Been Obvious Over Lee, Praphanphoj, Thibault, and Carducci.....32

*Petition for Inter Partes Review of U.S. Patent No. 9,561,197*

1.	Administering GPB to Treat UCD Patients Was Well-Known In the Art. ....	32
2.	A POSA Would Have Had a Reason to Determine a Subject’s PAA:PAGN Ratio. ....	33
3.	A POSA Would Have Had a Reason to Determine if a Subject’s Plasma PAA:PAGN Ratio Was Outside a Target Range of 1 to 2 or 2.5 and Adjust the Dose of GPB Accordingly. ....	40
4.	A POSA Would Have Had a Reasonable Expectation of Successfully Practicing the Claimed Methods. ....	42
B.	Objective Indicia of Nonobviousness Do Not Weigh In Favor of Patentability of Claims 1 and 2. ....	44
1.	No Unexpected Superior Results. ....	45
2.	No Long-Felt Need or Failure of Others. ....	47
3.	No Commercial Success. ....	48
4.	Alleged Copying By Generic Drug Makers Is Irrelevant. ....	50
5.	No Teaching Away. ....	50
VII.	CONCLUSION. ....	50
VIII.	MANDATORY NOTICES (37 C.F.R. § 42.8) ....	51

*Petition for Inter Partes Review of U.S. Patent No. 9,561,197*

**EXHIBIT LIST**

<b>Exhibit No.</b>	<b>Description</b>
1001	Scharschmidt, B. and Mokhtarani, M., U.S. Patent No. 9,561,197 (filed Sept. 11, 2012; issued Feb. 7, 2017) (“the ’197 patent”)
1002	Declaration of Neal Sondheimer, M.D., Ph.D.
1003	<i>Curriculum Vitae</i> of Neal Sondheimer, M.D., Ph.D.
1004	Lee, B., <i>et al.</i> , <i>Phase 2 Comparison of a Novel Ammonia Scavenging Agent with Sodium Phenylbutyrate in Patients with Urea Cycle Disorders: Safety, Pharmacokinetics and Ammonia Control</i> , MOLECULAR GENETICS METABOLISM, 100: 221-28 (2010) (“Lee”)
1005	Praphanphoj, V., <i>et al.</i> , <i>Three Cases of Intravenous Sodium Benzoate and Sodium Phenylacetate Toxicity Occurring in the Treatment in the Treatment of Acute Hyperammonaemia</i> , J. INHERIT. METAB. DIS., 23: 129-36 (2000) (“Praphanphoj”)
1006	Thibault, A., <i>et al.</i> , <i>A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer</i> , CANCER RESEARCH, 54: 1690-94 (1994) (“Thibault”)
1007	Carducci, M.A., <i>et al.</i> , <i>A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule</i> , CLINICAL CANCER RESEARCH, 7: 3047-55 (2001) (“Carducci”)
1008	Msall, M., <i>et al.</i> , <i>Neurologic Outcome in Children with Inborn Errors of Urea Synthesis — Outcome of Urea-Cycle Enzymopathies</i> , NEW ENGLAND JOURNAL OF MEDICINE, 310: 1500-05 (1984)
1009	File History for U.S. Patent No. 9,561,197
1010	MacArthur, R.B., <i>et al.</i> , <i>Pharmacokinetics of Sodium Phenylacetate and Sodium Benzoate Following Intravenous Administration As Both a Bolus and Continuous Infusion to Healthy Adult Volunteers</i> , MOLECULAR GENETICS AND METABOLISM, 81: S67-S73 (2004)
1011	McGuire, B.M., <i>et al.</i> , <i>Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis</i> , HEPATOLOGY, 51: 2077-85 (2010)
1012	Buxton, I.L.O., <i>Goodman &amp; Gilman’s: The Pharmacological Basis of Therapeutics</i> , 1-39 (L. Brunton et al., eds., 11th ed. 2006)

**Petition for Inter Partes Review of U.S. Patent No. 9,561,197**

<b>Exhibit No.</b>	<b>Description</b>
1013	Ravicti Product Label, Revised: Apr. 2017
1014	Buphenyl Label, Revised: Apr. 2008
1015	Ammonul Label, Revised: Feb. 2005
1016	Center for Drug Evaluation and Research, NDA No. 203284, Summary Review
1017	Feillet, F. and Leonard, J.V., <i>Alternative Pathway Therapy for Urea Cycle Disorders</i> , J. INHER. METAB. DIS., 21: 101-11 (1998).
1018	Fernandes, J., <i>et al.</i> , <i>Inborn Metabolic Diseases Diagnosis and Treatment</i> , 214-222 (J. Fernandes et al., eds., 3d ed. 2000)
1019	Scientific Discussion for Ammonaps, EMEA, 1-12 (2005)
1020	Scharschmidt, B., U.S. Patent Appl. Pub. No. 2010/0008859 (filed Jan. 7, 2009; published Jan. 14, 2010)
1021	Scharschmidt, B., U.S. Patent Appl. Pub. No. 2012/0022157 (filed Aug. 27, 2009; published Jan. 26, 2012)
1022	Brusilow, <i>Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion</i> , PEDIATRIC RESEARCH, 29: 147-50 (1991)
1023	Brusilow, S.W., U.S. Patent No. 5,968,979 (filed Jan. 13, 1998; issued Oct. 19, 1999)
1024	Yang, D., <i>et al.</i> , <i>Assay of the Human Liver Citric Acid Cycle Probe Phenylacetylglutamine and of Phenylacetate in Plasma by Gas Chromatography-Mass Spectrometry</i> , ANALYTICAL BIOCHEMISTRY, 212: 277-82 (1993)
1025	Yamaguchi, M. and Nakamura, M., <i>Determination of Free and Total Phenylacetic Acid in Human and Rat Plasma by High-Performance Liquid Chromatography with Fluorescence Detection</i> , CHEM. PHARM. BULL., 35: 3740-45 (1987)
1026	Laryea, M.D., <i>et al.</i> , <i>Simultaneous LC-MS/MS Determination of Phenylbutyrate, Phenylacetate Benzoate and their Corresponding Metabolites Phenylacetylglutamine and Hippurate in Blood and Urine</i> , J. INHERITED METABOLIC DISEASES, 33: S321-S328 (2010)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.